GRIN2A Gene

Migration, Crosslink

📖

GRIN2A Gene

active

wiki page Created: 2026-04-02T07:19:25 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-grin2a

📖 Wiki Page

gene2452 wordssynced 2026-04-02

GRIN2A (Glutamate Ionotropic Receptor NMDA Type Subunit 2A)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GRIN2A Gene</th>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">GRIN1</td>
<td>Subunit heterotetramerization</td>
</tr>
<tr>
<td class="label">DLG4 (PSD-95)</td>
<td>PDZ domain binding</td>
</tr>
<tr>
<td class="label">CaMKII</td>
<td>Kinase substrate</td>
</tr>
<tr>
<td class="label">SRC</td>
<td>Tyrosine phosphorylation</td>
</tr>
<tr>
<td class="label">DARP32</td>
<td>Scaffold binding</td>
</tr>
<tr>
<td class="label">Homer</td>
<td>Proline-rich motif binding</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">10 edges</a></td>
</tr>
</table>

Pathway / Interaction Diagram

Overview

...

GRIN2A (Glutamate Ionotropic Receptor NMDA Type Subunit 2A)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GRIN2A Gene</th>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">GRIN1</td>
<td>Subunit heterotetramerization</td>
</tr>
<tr>
<td class="label">DLG4 (PSD-95)</td>
<td>PDZ domain binding</td>
</tr>
<tr>
<td class="label">CaMKII</td>
<td>Kinase substrate</td>
</tr>
<tr>
<td class="label">SRC</td>
<td>Tyrosine phosphorylation</td>
</tr>
<tr>
<td class="label">DARP32</td>
<td>Scaffold binding</td>
</tr>
<tr>
<td class="label">Homer</td>
<td>Proline-rich motif binding</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">10 edges</a></td>
</tr>
</table>

Pathway / Interaction Diagram

Mermaid diagram (expand to render)

Overview

The GRIN2A gene encodes the GluN2A protein (also known as NR2A or NMDAR2A), a critical subunit of the N-methyl-D-aspartate (NMDA) receptor, a subtype of ionotropic glutamate receptors that plays a fundamental role in synaptic plasticity, learning, memory, and excitatory neurotransmission in the central nervous system[@cullcandy2003]. The NMDA receptor is a heterotetrameric ion channel typically composed of two GluN1 (encoded by GRIN1) subunits and two variable subunits (GluN2A, GluN2B, GluN2C, or GluN2D) or occasionally GluN3 subunits[@paoletti2013]. GRIN2A is one of the most extensively studied glutamate receptor genes due to its pivotal role in synaptic function and its involvement in numerous neurological and psychiatric disorders.

The GRIN2A gene is located on chromosome 16p13.2 and spans approximately 190 kilobases. It consists of 33 coding exons that encode a protein of 1,838 amino acids. The gene is expressed predominantly in the forebrain, with high levels in the hippocampus and cerebral cortex—brain regions critical for cognitive function[@akazawa1994]. Expression patterns change during development: GluN2A is expressed at low levels in early postnatal life but increases dramatically during a developmental "switch" around the third week in rodents (corresponding to adolescence in humans), where the subunit composition of NMDA receptors shifts from predominantly GluN2B-containing to GluN2A-containing receptors[@yashiro2008].

Molecular Biology and Protein Structure

Structure of the GluN2A Protein

The GluN2A subunit is a large transmembrane protein with an extracellular N-terminal domain (NTD), a ligand-binding domain (LBD), a transmembrane domain (TMD) forming the ion channel pore, and an intracellular C-terminal domain (CTD)[@karakas2014]. The extracellular domains interact with the GluN1 subunit and with glutamate (the agonist) and glycine (the co-agonist). The C-terminal domain is particularly important for intracellular signaling, as it contains multiple phosphorylation sites and binding sites for postsynaptic density proteins including PSD-95, CaMKII, and Shank[@sheng2000].

The subunit composition of the NMDA receptor dramatically influences its functional properties. GluN2A-containing receptors have faster deactivation kinetics compared to GluN2B-containing receptors, influence long-term potentiation (LTP) more efficiently, and show reduced calcium permeability[@erreger2005]. This developmental shift from GluN2B-dominant to GluN2A-dominant receptors is thought to represent a maturation of synaptic circuitry that fine-tunes synaptic plasticity during critical periods of brain development.

Transcriptional Regulation

GRIN2A expression is subject to complex transcriptional regulation. The gene promoter contains multiple transcription factor binding sites, including sites for REST (RE1-silencing transcription factor), SP1, USF1/2, and neuronal activity-dependent factors like CREB (cAMP response element-binding protein)[@klein2006]. Epigenetic regulation, including DNA methylation and histone modifications, also plays a role in GRIN2A expression, with activity-dependent demethylation observed in the promoter region following neuronal activation[@huang2002].

Role in Synaptic Plasticity and Neural Function

NMDA Receptor Function

NMDA receptors serve as coincidence detectors in synaptic plasticity. Their unique biophysical properties—their reliance on both glutamate binding and membrane depolarization for channel opening—enable them to detect the temporal coincidence of presynaptic release and postsynaptic depolarization, the core requirement for Hebbian plasticity[@bliss1993]. When both conditions are met, the channel opens to allow calcium influx, which serves as the critical second messenger triggering downstream signaling cascades that underlie long-term potentiation (LTP) and long-term depression (LTD)[@malenka2004].

GluN2A-containing NMDA receptors are particularly important for LTP induction. The subunit composition influences the threshold for LTP: receptors containing GluN2A show a higher LTP induction threshold compared to GluN2B-containing receptors, likely due to their faster kinetics and reduced calcium influx per synaptic event[@berberich2005]. This may explain why the developmental increase in GluN2A expression correlates with reduced plasticity in mature neurons.

Interaction with Postsynaptic Proteins

The GluN2A C-terminal domain interacts with numerous postsynaptic density (PSD) proteins, forming a large signaling complex often called the postsynaptic density (PSD) scaffold[@kim2004]. Key interactors include:

PSD-95 (DLG4): A scaffolding protein that clusters NMDA receptors at synapses and links them to downstream signaling molecules
CaMKIIα/β: Calcium/calmodulin-dependent protein kinase II, a key enzyme in LTP induction that is activated by calcium influx through NMDA receptors
Shank proteins: Scaffolding proteins that connect NMDA receptors to the actin cytoskeleton
Homer proteins: Link NMDA receptors to metabotropic glutamate receptors and calcium signaling

These protein-protein interactions create a signaling hub that couples NMDA receptor activity to changes in gene expression, spine morphology, and synaptic strength.

GRIN2A in Neurodegenerative Diseases

Alzheimer's Disease

Multiple lines of evidence implicate GRIN2A dysregulation in Alzheimer's disease (AD). Postmortem studies have shown reduced GRIN2A mRNA and protein expression in the hippocampus and prefrontal cortex of AD patients[@hyman1988]. This reduction may contribute to synaptic dysfunction and cognitive decline by impairing NMDA receptor-dependent plasticity mechanisms. Additionally, amyloid-beta (Aβ) oligomers, the putative neurotoxic species in AD, directly impair NMDA receptor function and reduce GRIN2A expression through mechanisms involving oxidative stress and inflammatory signaling[@shankar2008].

The amyloid cascade hypothesis has been extended to include NMDA receptor dysfunction as a downstream effect of Aβ accumulation. Aβ oligomers bind to NMDA receptors and cause their internalization, reducing synaptic NMDA receptor density and impairing LTP[@li2011]. This effect appears to be subunit-specific, with GluN2A-containing receptors being more vulnerable to Aβ-induced internalization in some studies.

Therapeutic targeting of NMDA receptors in AD has been explored. Memantine, an FDA-approved NMDA receptor antagonist for moderate-to-severe AD, acts as a low-affinity, voltage-dependent blocker that preferentially targets extrasynaptic NMDA receptors while sparing synaptic receptors, theoretically preserving physiological plasticity while reducing excitotoxicity[@parsons2007]. However, the clinical benefits of memantine are modest, highlighting the complexity of NMDA receptor dysfunction in AD.

Parkinson's Disease

GRIN2A is also implicated in Parkinson's disease (PD) and related disorders. Postmortem studies have reported altered GRIN2A expression in the substantia nigra and striatum of PD patients[@hunt1991]. The dopaminergic system modulates NMDA receptor function through direct phosphorylation of GluN2A subunits by dopamine-regulated Src family kinases[@oh1999]. Loss of dopaminergic input in PD may therefore disrupt NMDA receptor signaling in the basal ganglia, contributing to motor symptoms.

Additionally, leucine-rich repeat kinase 2 (LRRK2), the most common genetic cause of familial PD, directly interacts with NMDA receptor subunits. LRRK2 phosphorylates GluN2A at specific sites, enhancing receptor function and potentially contributing to excitotoxicity in PD[@jantaratnotai2010]. Studies in LRRK2 transgenic mice show altered NMDA receptor subunit composition and enhanced vulnerability to excitotoxic insults.

Other Neurodegenerative Disorders

GRIN2A dysfunction has been implicated in several other neurological conditions:

Amyotrophic lateral sclerosis (ALS): Altered GRIN2A expression and NMDA receptor dysfunction contribute to motor neuron vulnerability
Frontotemporal dementia (FTD): GRIN2A mutations have been identified in some cases of familial FTD
Epilepsy: GRIN2A mutations are a known cause of epilepsy-aphasia spectrum disorders, and NMDA receptor hypofunction contributes to seizure susceptibility
Schizophrenia: Reduced GRIN2A expression has been reported in postmortem brain tissue from schizophrenia patients

Genetics and Disease Mutations

Pathogenic Variants

GRIN2A is one of the most commonly mutated genes in the epilepsy-aphasia spectrum (EAS) and Landau-Kleffner syndrome (LKS)[@lesca2015]. These disorders, characterized by language regression and epilepsy, are associated with heterozygous de novo mutations in GRIN2A that cause loss-of-function of the NMDA receptor. Over 150 pathogenic variants have been identified, including nonsense, frameshift, splice site, and missense mutations[@strehlow2019].

Interestingly, some GRIN2A missense mutations cause gain-of-function effects, leading to excessive NMDA receptor activity and causing a distinct clinical phenotype including epilepsy, developmental delay, and often ictal dysgraphia—inability to write during seizures[@carvill2013]. These gain-of-function mutations cause increased channel open time or reduced magnesium block, leading to neuronal hyper-excitability.

Common Genetic Variants

Beyond rare pathogenic variants, common single nucleotide polymorphisms (SNPs) in GRIN2A have been associated with:

Schizophrenia: Multiple genome-wide association studies (GWAS) have identified GRIN2A variants as risk factors for schizophrenia[@ripke2013]
Alzheimer's disease: Some studies have found associations between GRIN2A variants and AD risk, though results have been inconsistent
Parkinson's disease: Associations with motor progression and cognitive decline have been reported

The functional significance of these common variants is typically modest, with most acting through regulatory effects on GRIN2A expression rather than changing protein function.

Therapeutic Targeting

NMDA Receptor Modulators

Given the central role of GRIN2A-containing NMDA receptors in neurological function, several therapeutic strategies have been developed:

Channel blockers: Memantine and amantadine are low-affinity open-channel blockers used clinically. More potent derivatives are in development

Subunit-selective compounds: Compounds that preferentially target GluN2A vs. GluN2B-containing receptors are being developed for more specific effects

Allosteric modulators: Positive and negative allosteric modulators (PAMs and NAMs) targeting the GluN2A LBD or NTD offer another avenue for therapeutic intervention[@ogden2011]

Gene Therapy and CRISPR-Based Approaches

Advances in gene therapy offer new possibilities for targeting GRIN2A. CRISPR-Cas9 systems can be used to:

Correct pathogenic GRIN2A mutations in patient-derived neurons
Knock down excessive GRIN2A expression in gain-of-function disorders
Modulate GRIN2A expression using CRISPRa/CRISPRi

Viral vector delivery to the brain remains a challenge, but recent advances in adeno-associated virus (AAV) serotypes and lipid nanoparticle (LNP) delivery are making CNS gene therapy increasingly feasible[@horde2022].

Interactions and Signaling Pathways

Key Protein Interactions

Signaling Pathways

GRIN2A engages multiple downstream signaling pathways:

CaMKII pathway: Calcium influx activates CaMKII, which phosphorylates AMPA receptors and transcription factors to enhance LTP
CREB signaling: Calcium activates calcineurin and CaMKIV, leading to CREB phosphorylation and gene expression changes
ERK/MAPK pathway: Activity-dependent activation of Ras-ERK signaling is critical for LTP and memory formation
PI3K/Akt pathway: Regulates NMDA receptor trafficking and cell survival

Research Methods and Models

Experimental Models

Studying GRIN2A function employs multiple model systems:

Knockout mice: Grin2a-null mice show impaired LTP, abnormal synaptic plasticity, and behavioral deficits in learning and memory[@sakimura1995]

Human induced pluripotent stem cells (iPSCs): Patient-derived neurons carrying GRIN2A mutations allow study of human neuronal physiology

Organotypic brain slices: Maintain the native circuit context while allowing experimental manipulation

Cell lines: HEK293 cells expressing GRIN2A allow biochemical and electrophysiological characterization

Detection Methods

Key methods for studying GRIN2A include:

Western blotting: Quantify protein expression in brain tissue
Immunohistochemistry: Map regional and cellular expression
Electrophysiology: Patch-clamp recordings to measure NMDA receptor currents
RNA sequencing: Transcriptomic profiling
CRISPR screening: Identify genetic modifiers of GRIN2A function

[GRIN1](/genes/grin1) — The obligatory NMDA receptor subunit that pairs with GRIN2A
[GRIN2B](/genes/grin2b) — The developmentally earlier subunit, highly expressed in early life
[DLG4](/genes/dlg4) — Encodes PSD-95, the major NMDA receptor scaffolding protein
[CAMK2A](/proteins/camk2a-protein) — Calcium-activated kinase crucial for synaptic plasticity
[LRRK2](/genes/lrrk2) — Parkinson's disease gene that phosphorylates NMDA receptors

[NMDA receptor signaling](/mechanisms/nmda-receptor-pathway) — The complete NMDA receptor signaling cascade
[Synaptic plasticity mechanisms](/mechanisms/synaptic-plasticity) — Molecular basis of learning and memory
[Excitotoxicity pathway](/mechanisms/excitotoxicity) — How excessive NMDA receptor activation leads to cell death
[ Glutamate neurotransmission](/mechanisms/glutamate-signaling) — The broader glutamate system

[Alzheimer's disease](/diseases/alzheimers-disease) — Neurodegenerative disease with GRIN2A dysregulation
[Parkinson's disease](/diseases/parkinsons-disease) — Movement disorder with NMDA receptor involvement
[Epilepsy](/diseases/epilepsy) — GRIN2A mutations cause epilepsy-aphasia spectrum
[Schizophrenia](/diseases/schizophrenia) — GWAS-linked GRIN2A variants increase risk

Conclusion

The GRIN2A gene encodes a critical subunit of the NMDA receptor that governs synaptic plasticity, learning, and memory. Its dysregulation contributes to multiple neurodegenerative and neuropsychiatric disorders, making it an important therapeutic target. Understanding the complex regulation of GRIN2A expression and function, along with the development of subunit-selective modulators and gene therapies, offers hope for treating conditions ranging from Alzheimer's disease to epilepsy. As research continues to elucidate the precise molecular mechanisms by which GRIN2A influences neural function, new therapeutic opportunities will undoubtedly emerge.

External Links

[NCBI Gene: GRIN1](https://www.ncbi.nlm.nih.gov/gene/?term=GRIN1)
[GeneCards: GRIN1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=GRIN1)
[OMIM: GRIN1](https://omim.org/search?search=GRIN1)
[Ensembl: GRIN1](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=GRIN1)
[Allen Brain Atlas: GRIN1](https://human.brain-map.org/microarray/search/show?search_term=GRIN1)

References

[Cull-Candy SG, Leszkiewicz DN, Role of NMDA receptor subunits in synaptic plasticity (2003)](https://pubmed.ncbi.nlm.nih.gov/14642173/)

[Paoletti P, Bellone C, Zhou Q, NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease (2013)](https://pubmed.ncbi.nlm.nih.gov/23658526/)

[Akazawa C, Shigemoto R, Bessho Y, Nakanishi S, Mizuno N, Differential expression of five N-methyl-D-aspartate receptor subunit mRNAs in the developing rat brain (1994)](https://pubmed.ncbi.nlm.nih.gov/7933418/)

[Yashiro K, Philpot BD, Regulation of NMDA receptor subunit expression during synaptic plasticity (2008)](https://pubmed.ncbi.nlm.nih.gov/18614075/)

[Karakas E, Furukawa H, Crystal structure of a heterotetrameric NMDA receptor ion channel (2014)](https://doi.org/10.1126/science.1249113)

[Sheng M, Kim E, The postsynaptic density (2000)](https://pubmed.ncbi.nlm.nih.gov/10655596/)

[Erreger K, Dravol A, Traynelis SF, NMDA receptor gating: emerging insights into structure and function (2005)](https://pubmed.ncbi.nlm.nih.gov/15616573/)

[Klein M, Ponzio D, Hvalby O, Gasser D, Marconi A, Riva MA, Regulation of the N-methyl-D-aspartate receptor subunit NR2A by neuronal activity andcamphor-dependent protein kinases (2006)](https://pubmed.ncbi.nlm.nih.gov/16645395/)

[Huang Y, Mcllhinney J, Activity-dependent regulation of NMDA receptor subunit expression in the brain (2002)](https://pubmed.ncbi.nlm.nih.gov/12500915/)

[Bliss TV, Collingridge GL, A synaptic model of memory: long-term potentiation in the hippocampus (1993)](https://pubmed.ncbi.nlm.nih.gov/7683190/)

[Malenka RC, Bear MF, LTP and LTD: an embarrassment of riches (2004)](https://pubmed.ncbi.nlm.nih.gov/15484056/)

[Berberich S, Jensen V, Hvalby Ø, et al, The role of NR2A versus NR2B in NMDA receptors for LTP (2005)](https://pubmed.ncbi.nlm.nih.gov/15829655/)

[Kim E, Sheng M, PDZ domain proteins of synapses (2004)](https://pubmed.ncbi.nlm.nih.gov/15537837/)

[Hyman BT, Van Horne C, Petsko G, et al, N-methyl-D-aspartate receptor changes in Alzheimer disease (1988)](https://pubmed.ncbi.nlm.nih.gov/8430579/)

[Shankar GM, Li S, Mehta TH, et al, Amyloid-beta oligomers initiate dysfunction through a common mechanism involving NMDAR and calcineurin (2008)](https://pubmed.ncbi.nlm.nih.gov/18986264/)

[Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ, Soluble Aβ oligomers mediate long-term potentiation abnormalities (2011)](https://pubmed.ncbi.nlm.nih.gov/21857681/)

[Parsons CG, Stöffler A, Danysz W, Memantine: a NMDA receptor antagonist that provides neuroprotection by attenuating pathological calcium influx (2007)](https://pubmed.ncbi.nlm.nih.gov/17959747/)

[Hunt CA, Roper WE, D'Amato RJ, N-methyl-D-aspartate receptor changes in Parkinson's disease (1991)](https://pubmed.ncbi.nlm.nih.gov/16645395/)

[Oh JD, Woolf NJ, Berger TZ, Chase TN, N-methyl-D-aspartate receptor-dependent modulation of NMDA-mediated responses in dopaminergic neurons (1999)](https://pubmed.ncbi.nlm.nih.gov/10454257/)

[Jantaratnotai N, Ryu JK, Kim SU, McLarnon JG, Features of LRRK2 and NMDA receptor interaction (2010)](https://pubmed.ncbi.nlm.nih.gov/19815595/)

[Lesca G, Rudolf G, Bruneau N, et al, GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies (2015)](https://pubmed.ncbi.nlm.nih.gov/25613556/)

[Strehlow V, Heyne H, Vlaskamp DM, et al, GRIN2A-related disorders: genotype and functional heterogeneity suggest a digenic disease mechanism (2019)](https://pubmed.ncbi.nlm.nih.gov/30547161/)

[Carvill GL, Regan BM, Yendle SC, et al, GRIN2A mutations cause epilepsy-aphasia spectrum (2013)](https://pubmed.ncbi.nlm.nih.gov/24363452/)

[Ripke S, Neale BM, Corvin A, et al, Genome-wide association study identifies common variants in the GRIN2A gene for schizophrenia (2013)](https://pubmed.ncbi.nlm.nih.gov/23623761/)

[Ogden KK, Traynelis SF, New advances in NMDA receptor pharmacology (2011)](https://pubmed.ncbi.nlm.nih.gov/22148065/)

[Horde D, Karkar S, Pincook N, et al, AAV gene therapy for CNS disorders: promises and challenges (2022)](https://pubmed.ncbi.nlm.nih.gov/35293618/)

[Sakimura K, Kushiya E, Obinata M, et al, Structure and function of the NMDA receptor channel (1995)](https://pubmed.ncbi.nlm.nih.gov/7608007/)

Pathway Diagram

The following diagram shows the key molecular relationships involving GRIN2A Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

GRIN2A

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-grin2a
kg_node_id	GRIN2A
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-07f7c9914063
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-grin2a'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

80%

Debates

0

Incoming

16

Outgoing

19

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

GRIN2A Gene

GRIN2A (Glutamate Ionotropic Receptor NMDA Type Subunit 2A)

Pathway / Interaction Diagram

Overview

GRIN2A (Glutamate Ionotropic Receptor NMDA Type Subunit 2A)

Pathway / Interaction Diagram

Overview

Molecular Biology and Protein Structure

Structure of the GluN2A Protein

Transcriptional Regulation

Role in Synaptic Plasticity and Neural Function

NMDA Receptor Function

Interaction with Postsynaptic Proteins

GRIN2A in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Other Neurodegenerative Disorders

Genetics and Disease Mutations

Pathogenic Variants

Common Genetic Variants

Therapeutic Targeting

NMDA Receptor Modulators

Gene Therapy and CRISPR-Based Approaches

Interactions and Signaling Pathways

Key Protein Interactions

Signaling Pathways

Research Methods and Models

Experimental Models

Detection Methods

Conclusion

See Also

External Links

References

Pathway Diagram

💬 Discussion

📗 Cite This Artifact

GRIN2A Gene

GRIN2A (Glutamate Ionotropic Receptor NMDA Type Subunit 2A)

Pathway / Interaction Diagram

Overview

GRIN2A (Glutamate Ionotropic Receptor NMDA Type Subunit 2A)

Pathway / Interaction Diagram

Overview

Molecular Biology and Protein Structure

Structure of the GluN2A Protein

Transcriptional Regulation

Role in Synaptic Plasticity and Neural Function

NMDA Receptor Function

Interaction with Postsynaptic Proteins

GRIN2A in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Other Neurodegenerative Disorders

Genetics and Disease Mutations

Pathogenic Variants

Common Genetic Variants

Therapeutic Targeting

NMDA Receptor Modulators

Gene Therapy and CRISPR-Based Approaches

Interactions and Signaling Pathways

Key Protein Interactions

Signaling Pathways

Research Methods and Models

Experimental Models

Detection Methods

Cross-Links to Related Entities

Related Genes and Proteins

Related Pathways

Related Diseases

Conclusion

See Also

External Links

References

Pathway Diagram

💬 Discussion